Literature DB >> 16718833

Controversies in the treatment of gastroesophageal reflux and achalasia.

Kurt-E Roberts1, Andrew-J Duffy, Robert-L Bell.   

Abstract

The immense success of laparoscopic surgery as an effective treatment of gastroesophageal reflux disease (GERD) and achalasia has established minimal invasive surgery as the gold standard for these two conditions with lower morbidity and mortality, shorter hospital stay, faster convalescence, and less postoperative pain. One controversy in the treatment of GERD evolves around laparoscopic antireflux surgery (LARS) as the preferred treatment for Barrett's esophagus and the procedure's potential to reduce the risk of adenocarcinoma of the esophagus. GERD has also been associated with respiratory symptoms, asthma and laryngeal injury, and a second controversy prompts discussions about whether total or partial fundoplication is the more appropriate treatment for GERD. A new and promising alternative in the treatment of GERD is endoluminal therapy. Three types of this new treatment option will be discussed: radiofrequency energy delivered to the lower esophageal sphincter, the creation of a mechanical barrier at the gastroesophageal junction, and the direct endoscopic tightening of the lower esophageal sphincter. Laparoscopic surgery is discussed not only as a very effective treatment for GERD but also as permanent cure for achalasia. This review analyzes the three most important treatment options for achalasia: medications, pneumatic dilatation, and surgical therapy. Medications as the only true non-invasive option in the treatment of achalasia are not as effective as LARS because of their short half-life and variable absorption due to the poor esophageal emptying. The second treatment option, pneumatic dilatation, involves the stretching of the lower esophagus and is still considered the most effective non-surgical treatment for achalasia. Finally, surgical therapy for achalasia and the two major controversies concerning this laparoscopic treatment are discussed. The first involves the extent to which the myotomy is extended onto the stomach, and the second concerns the necessity and type of antireflux procedure to prevent GERD after myotomy. LARS and laparoscopic Heller myotomy are the agreed upon as the gold standards for surgical treatment of GERD and achalasia, respectively. In the hands of an experienced laparoscopic surgeon both are safe and effective treatments for patients with excellent subjective and objective long-term results with at least 90% patient satisfaction.

Entities:  

Mesh:

Year:  2006        PMID: 16718833      PMCID: PMC4087956          DOI: 10.3748/wjg.v12.i20.3155

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

Review 1.  Complications and results of primary minimally invasive antireflux procedures: a review of 10,735 reported cases.

Authors:  M A Carlson; C T Frantzides
Journal:  J Am Coll Surg       Date:  2001-10       Impact factor: 6.113

2.  [A simple operation for control of reflux esophagitis].

Authors:  R NISSEN
Journal:  Schweiz Med Wochenschr       Date:  1956-05-18

3.  Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study.

Authors:  C Fibbe; P Layer; J Keller; U Strate; A Emmermann; C Zornig
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

4.  Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia.

Authors:  J Mikaeli; A Fazel; G Montazeri; M Yaghoobi; R Malekzadeh
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

Review 5.  Pharmacologic therapy in treating achalasia.

Authors:  W A Hoogerwerf; P J Pasricha
Journal:  Gastrointest Endosc Clin N Am       Date:  2001-04

6.  Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery.

Authors:  T M Farrell; W S Richardson; T L Trus; C D Smith; J G Hunter
Journal:  Br J Surg       Date:  2001-12       Impact factor: 6.939

7.  Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication.

Authors:  Reginald V N Lord; Anna Kaminski; Stefan Oberg; David J Bowrey; Jeffrey A Hagen; Steven R DeMeester; Lelan F Sillin; Jeffrey H Peters; Peter F Crookes; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2002 Jan-Feb       Impact factor: 3.452

8.  Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.

Authors:  L Lundell; P Miettinen; H E Myrvold; S A Pedersen; B Liedman; J G Hatlebakk; R Julkonen; K Levander; J Carlsson; M Lamm; I Wiklund
Journal:  J Am Coll Surg       Date:  2001-02       Impact factor: 6.113

9.  Long-term outcome of antireflux surgery in patients with Barrett's esophagus.

Authors:  W L Hofstetter; J H Peters; T R DeMeester; J A Hagen; S R DeMeester; P F Crookes; P Tsai; F Banki; C G Bremner
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

10.  The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial.

Authors:  George Triadafilopoulos; John K DiBaise; Timothy T Nostrant; Neil H Stollman; Paul K Anderson; M Michael Wolfe; Richard I Rothstein; John M Wo; Douglas A Corley; Marco G Patti; Louis V Antignano; John S Goff; Steven A Edmundowicz; Donald O Castell; John C Rabine; Michael S Kim; David S Utley
Journal:  Gastrointest Endosc       Date:  2002-02       Impact factor: 9.427

View more
  9 in total

1.  Laparoscopic Heller myotomy plus Dor fundoplication in 137 achalasic patients: results on symptoms relief and successful outcome predictors.

Authors:  Paolo Parise; Stefano Santi; Biagio Solito; Giovanni Pallabazzer; Mauro Rossi
Journal:  Updates Surg       Date:  2011-02-22

2.  Evidence-based appraisal in laparoscopic Nissen and Toupet fundoplications for gastroesophageal reflux disease.

Authors:  Cheng-Xiang Shan; Wei Zhang; Xiang-Min Zheng; Dao-Zhen Jiang; Sheng Liu; Ming Qiu
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

3.  Surgical treatment for nonspecific esophageal motility disorders.

Authors:  Takanori Inose; Tatsuya Miyazaki; Shigemasa Suzuki; Naritaka Tanaka; Makoto Sakai; Akihiko Sano; Takehiko Yokobori; Makoto Sohda; Masanobu Nakajima; Minoru Fukuchi; Hiroyuki Kato; Hiroyuki Kuwano
Journal:  Surg Today       Date:  2012-12-18       Impact factor: 2.549

Review 4.  Meta-analysis of randomized and controlled treatment trials for achalasia.

Authors:  Lan Wang; You-Ming Li; Lan Li
Journal:  Dig Dis Sci       Date:  2008-12-24       Impact factor: 3.199

Review 5.  Recent trends in endoscopic management of achalasia.

Authors:  Salvatore Tolone; Paolo Limongelli; Gianmattia Del Genio; Luigi Brusciano; Antonio Russo; Lorenzo Cipriano; Marco Terribile; Giovanni Docimo; Roberto Ruggiero; Ludovico Docimo
Journal:  World J Gastrointest Endosc       Date:  2014-09-16

6.  The long-term outcome of balloon dilation versus botulinum toxin injection in patients with primary achalasia.

Authors:  Do Hoon Kim; Hwoon-Yong Jung
Journal:  Korean J Intern Med       Date:  2014-10-31       Impact factor: 2.884

7.  Single-site Nissen fundoplication versus laparoscopic Nissen fundoplication.

Authors:  Nicole E Sharp; John Vassaur; F Paul Buckley
Journal:  JSLS       Date:  2014 Jul-Sep       Impact factor: 2.172

8.  Heller myotomy versus endoscopic balloon dilatation for achalasia: A single center experience.

Authors:  Felix Nickel; Philip C Müller; Javier R de la Garza; Christian Tapking; Laura Benner; Lars Fischer; Daniel C Steinemann; Christian Rupp; Georg R Linke; Beat P Müller-Stich
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 9.  A controversy that has been tough to swallow: is the treatment of achalasia now digested?

Authors:  Garrett R Roll; Charlotte Rabl; Ruxandra Ciovica; Sofia Peeva; Guilherme M Campos
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.